×

Water exercise beats standard PT for MS fatigue, balance issues

Aquatic therapy significantly eased fatigue and improved balance in multiple sclerosis (MS) patients in a clinical trial in Greece, outperforming results from a control group who participated in a conventional physiotherapy program. “Our work suggests that incorporating [aquatic therapy] into MS care can meaningfully alleviate…

Welcome December

I am a day late with saying this, but happy December to y’all! Can you believe it is already December? Where has the year gone? It seems the older I get, the faster the years fly by. At this moment, which I know can change…

Oral bacteria tied to more severe multiple sclerosis symptoms

People with multiple sclerosis (MS) who have higher levels of Fusobacterium nucleatum in the mouth — bacteria that can contribute to periodontitis, a serious gum infection — may be more likely to experience more severe symptoms, according to a study from Japan. This finding adds…

NEDA Fudge and Alemtuzumab

Tweet No evidence of disease control is typically no relapse no MRI lesions and no progression. Whilst as mentioned I think progtrssion is a composite surrogate of different biologies the question is how good are drugs at inducing NEDA. Here we hear about alemtuzumab and…

Know One Know them All?

Tweet Are all the anti-CD20 depleting antibodies the same? This study aims to show if rituximab is inferior to ocrelizumab, MSBase said it was. I would ask why? What biology is different?….They are clearly not all the the same in how they do things but…

Kelly Montelo-Murphy – MSAA’s December 2025 Artist of the Month

MSAA features the work of many talented artists affected by multiple sclerosis as part of our annual MSAA Art Showcase. Each month we share these artists’ inspiring stories and beautiful artwork with you as our Artist of the Month. This month, we celebrate Kelly Montelo-Murphy as December’s … Continue reading → Source:…

Know One Know them All?

Tweet Are all the anti-CD20 depleting antibodies the same? This study aims to show if rituximab is inferior to ocrelizumab, MSBase said it was. I would ask why? What biology is different?…They are clearly not all the same in how they do things but they…